This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Champs, C.
Right arrow Articles by Nordmann, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Champs, C.
Right arrow Articles by Nordmann, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2002, p. 3031-3034, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3031-3034.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Prospective Survey of ß-Lactamases Produced by Ceftazidime- Resistant Pseudomonas aeruginosa Isolated in a French Hospital in 2000

Christophe De Champs,1* Laurent Poirel,2 Richard Bonnet,1 Danielle Sirot,1 Catherine Chanal,1 Jacques Sirot,1 and Patrice Nordmann2

Service de Bactériologie, Faculté de Médecine, Université d'Auvergne, 63001 Clermont-Ferrand,1 Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, 94275 Le Kremlin-Bicêtre, France2

Received 24 October 2001/ Returned for modification 7 February 2002/ Accepted 14 May 2002


arrow
ABSTRACT
 
In 2000, at the Université d'Auvergne teaching hospital in Clermont-Ferrand, France, 44 (6.2%) strains of Pseudomonas aeruginosa were found to be resistant to ceftazidime. After genotyping, 34 strains were selected. Nine had an additional ß-lactamase: OXA-21 (n = 6), PSE-1 (CARB-2) (n = 2), or PER-1 (n = 1). Ceftazidime resistance was related solely to the overproduction of the cephalosporinase in 30 strains. Sequencing of five blaAmpC genes encoding cephalosporinases with different pIs showed 99% identity with the ampC gene of P. aeruginosa PAO1.


arrow
TEXT
 
Resistance to extended-spectrum cephalosporins in Pseudomonas aeruginosa is associated in most cases with the overproduction of a naturally produced cephalosporinase (19). Derepression of this AmpC ß-lactamase affects all ß-lactams to various extents, which may lead to the misdetection of other acquired ß-lactamases. Enzymes hydrolyzing extended-spectrum cephalosporins of Ambler classes A, B, and D have been reported in P. aeruginosa (19). Among the extended-spectrum ß-lactamases (ESBLs) of class A, TEM-4 (22), TEM-24 (15), TEM-42 (16), PER-1 (18), SHV-2a (19), VEB-1 (21), and GES-2 (26) have been encountered.

Class B enzymes, IMP-1 (33), VIM-1 (10), VIM-2 (23), and VIM-related enzymes (11), hydrolyze carbapenems in addition to extended-spectrum cephalosporins.

The extended-spectrum class D enzymes are OXA-2 derivatives (OXA-15 [4] and OXA-32 [24]), OXA-10 derivatives (OXA-11 [7], OXA-14 [3], OXA-16 [5], OXA-17 [6], OXA-19 [17], and OXA-28 [25]), and OXA-18 (20).

Other mechanisms implicated in resistance to ß-lactams in P. aeruginosa are impermeability of the outer membrane and increased efflux (12) The aim of this study was to characterize the ß-lactamases produced by ceftazidime-resistant P. aeruginosa isolates.

Of the 713 nonduplicate P. aeruginosa strains isolated from the Université d'Auvergne teaching hospital in Clermont-Ferrand, France, between 1 January and 30 September 2000, 44 (6.2%) were resistant to ceftazidime, as determined by the disk diffusion method on Mueller-Hinton agar according to the recommendations of the Antibiogram Committee of the French Society for Microbiology (zone diameter, <15 mm; www.sfm.asso.fr/Sect4/atbuk.html). This prevalence of ceftazidime resistance was higher than the 4% prevalence in 1996 reported in a previous French national multicenter study (2). Isolates were identified with the ID 32 GN system (BioMérieux, Marcy l'Etoile, France). A duplicate isolate was defined as an isolate with the same antibiotic resistance phenotype as another isolate from the same patient during the same course of infection. The 44 strains were typed by random amplification of polymorphic DNA (RAPD) with two primers, ERIC-2 and 208, as described previously (Table 1) (14, 30). Isoelectric focusing analysis was performed with 6% polyacrylamide gels containing ampholines (Amersham Pharmacia Biotech, Uppsala, Sweden) with a pH range of 3.5 to 10, as reported previously (19). Among the 44 strains, 34 were selected on the basis of antibiotic resistance patterns, pIs, and patterns by RAPD analysis (Table 2). The chromosomal cephalosporinases focused at five pIs: 8.4 (n = 13), 8.0 (n = 8), 8.0 and 8.4 (n = 7), 7.8 (n = 4), and 8.6 (n = 2). Three additional ß-lactamases were found at pIs 7.0 (n = 6), 5.7 (n = 2), and 5.4 (n = 1). The strains were distributed into 33 different RAPD profiles.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Oligonucleotides used as primers for amplification and/or sequencing


View this table:
[in this window]
[in a new window]
  		TABLE 2. Characteristics of the 34 ceftazidime-resistant P. aeruginosa isolates

The MICs of drugs alone or in combination with a fixed concentration of clavulanate (2 µg/ml) and tazobactam (4 µg/ml) were determined by the dilution method in Mueller-Hinton agar with an inoculum of 104 CFU per spot, as described previously (20) (Table 2). The MICs of ceftazidime were in a narrow range from 32 to 128 µg/ml. The MICs of ticarcillin ranged from 64 to 2,048 µg/ml. The use of clavulanate did not restore susceptibility to ticarcillin. The MICs of piperacillin were between 16 and 256 µg/ml, and the MICs of aztreonam were between 16 and 128 µg/ml. The strains were moderately resistant to cefepime (MICs, 8 to 64 µg/ml). Fifteen strains were resistant to imipenem (MICs, >8 µg/ml), and of these, three were resistant to meropenem (MICs, >8 µg/ml).

Cephalosporinase inhibition, evaluated by the disk diffusion method on Mueller-Hinton agar containing cloxacillin at 250 or 500 µg/ml, was considered significant when the ceftazidime zone diameter increased by >10 mm. P. aeruginosa PAO1 was used as the reference strain (8). For 25 strains which did not have pI values that might correspond to those for an additional ß-lactamase, ceftazidime activity was partially restored by cloxacillin at 250 µg/ml (n = 15) or only by cloxacillin at 500 µg/ml (n = 10). For these 25 strains without an additional ß-lactamase, the level of production of the AmpC enzymes was measured by determination of their specific ß-lactamase activities. Cultures were grown overnight at 37°C in 3 liters of brain heart infusion (Biokar Diagnostics, Beauvais, France). Bacterial suspensions were disrupted by sonication and centrifuged as described previously (19). The supernatants were dialyzed against 3 liters of 100 mM NaCl overnight at 4°C. Then, the specific ß-lactamase activities of the crude extracts were determined by a computerized microacidimetric method described elsewhere (9) with 225 mM benzylpenicillin as the substrate. The total protein concentration in the enzyme preparation was estimated by a protein assay (Bio-Rad, Richmond, Calif.) with bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.) as the standard. One unit of specific ß-lactamase activity was defined as the amount of enzyme which hydrolyzes 1 µmol of benzylpenicillin per min and per mg of protein at 37°C and at pH 7. For 21 strains the specific activity was 100- to 1,000-fold greater than that of PAO1, with values ranging from 124 to 15,373 mU mg-1 (Table 2). Variations in levels of resistance to ceftazidime were weakly related to different levels of enzyme overproduction (i.e., an MIC of 64 µg/ml corresponds to specific activities of 52 mU mg-1 for strain 33 and 15,373 mU mg-1 for strain 5).

The ampC genes of the strains that produced five cephalosporinases with different pI values were amplified with primers AMPC-PAC and AMPC-PAD (Table 1) under the following conditions: 94°C for 5 min and then 30 cycles of 94°C for 1 min, 50°C for 3 min, and 72°C for 3 min, with a single final extension at 72°C for 15 min. The PCR products were sequenced with the primers AMPC-PAD, AMPC-PAG, AMPC-28, and AMPC-PAB1 (Table 1). Sequence analysis showed a low level of sequence diversity (0.17 to 0.75%) and 99% nucleotide identity with the ampC gene of P. aeruginosa strain PAO1 (GenBank accession no. X54719). Compared to the PAO1 ampC gene sequence (8), all ampC genes encoding enzymes with pIs different from 8.0 harbored the mutation A866->G, which led to the substitution Thr105->Ala (Table 3).


View this table:
[in this window]
[in a new window]
  		TABLE 3. Substitution in blaAmpC genes according to the pI value for each cephalosporinase and comparison with the sequence of the blaAmpC gene of P. aeruginosa strain PAO1 (pI 8.0)

Genes encoding enzymes of pI 8.0 + 8.4 and pI 8.4 harbored a mutation at position 1166 that led to the substitution Val205->Leu. The ampC gene encoding the enzyme of pI 7.8 harbored the mutation G789->A, which led to the substitution Arg79->Gln, and that encoding the enzyme of pI 8.6 harbored the mutation T1080->G, which led to the substitution Leu176->Arg. The Arg79->Gln substitution is associated with a change in charges and may have been responsible for the decrease in the pI value from 8.0 to 7.8, as reported previously (28). However, enzymes with identical pIs do not necessarily share identical amino acid sequences, and the different pIs suggested that some bands correspond to cleaved derivatives (isoenzymes) of the cephalosporinase, as reported previously (32).

For eight of the nine strains with an additional ß-lactamase, ceftazidime activity was restored only by cloxacillin at 500 µg/ml (strains 18 to 25), and so ceftazidime resistance was very likely due to hydrolysis by the derepressed chromosomal cephalosporinase. For strain 4 the activity of ceftazidime was not restored by cloxacillin at 500 µg/ml. Strain 4 was the only one which had a positive modified disk synergy test result with ceftazidime and clavulanate (27). The genes of the six ß-lactamases with a pI of 7.0 were amplified with OXA-2 primers (primers OXA-2,3 and OXB-2,3). Nucleotide sequence analysis of the blaOXA PCR products revealed a blaOXA-21 sequence with only one silent mutation (T697->C) in the genes of four isolates compared to the sequence of blaOXA-21 previously reported for Acinetobacter baumannii (31) (EMBL database accession no. Y10693). The six strains that produced OXA-21 had different RAPD patterns (data not shown). To our knowledge, this is the first report of OXA-21 in P. aeruginosa.

The blaPSE-1 gene was detected in two strains by PCR with primers OC1 and OC3 (Table 1), and a protein with a pI of 5.7 conferred a very high level of resistance to ticarcillin (MICs, >2,048 µg/ml) and ticarcillin-clavulanate (MICs, 256/1,024 µg/ml).

The blaPER-1 gene of the strain producing the ß-lactamase with a pI of 5.4 was identified by PCR with primers PER-A and PER-B (Table 1) and sequencing. Epidemics caused by strains with this enzyme, previously reported in Turkey (29) and Italy (13), are now observed in France.

The carbapenem resistance observed in 15 strains was not related to enzymatic hydrolysis by a carbapenem-hydrolyzing ß-lactamase. Although several ESBLs were reported in P. aeruginosa, their prevalences were very low in our study.


arrow
ACKNOWLEDGMENTS
 
We thank Rolande Perroux, Marlène Jan, and Dominique Rubio for technical assistance. We are also grateful to J. Watts for reading the English manuscript.

This work was supported in part by a grant from the Ministère de l'Education Nationale, de la Recherche et de la Technologie.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Faculté de Médecine, Service de Bactériologie, 28, place Henri Dunant, 63001 Clermont-Ferrand Cedex, France. Phone: 33 4 73 17 81 54. Fax: 33 4 73 27 74 94. E-mail: christophe.dechamps{at}u-clermont1.fr. Back


arrow
REFERENCES
 
    1
  1. Arlet, G., and A. Philippon. 1991. Construction by polymerase chain reaction and intragenic DNA probes for three main types of transferable ß-lactamases (TEM, SHV, CARB). FEMS Microbiol. Lett. 82:19-26.[CrossRef]
    2. 2
  2. Cavallo, J. D., R. Fabre, F. Leblanc, M. H. Nicolas-Chanoine, A. Thabaut, and the GERPB. 2000. Antibiotic susceptibility and mechanisms of ß-lactam resistance in 1310 strains of Pseudomonas aeruginosa: a French multicentre study (1996). J. Antimicrob. Chemother. 46:133-136.[Abstract/Free Full Text]
    3. 3
  3. Danel, F., L. M. C. Hall, D. Gur, and D. M. Livermore. 1995. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) ß-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1881-1884.[Abstract]
    4. 4
  4. Danel, F., M. Lucinda, C. Hall, D. Gur, and D. M. Livermore. 1997. OXA-15, an extended-spectrum variant of OXA-2 ß-lactamase isolated from a Pseudomonas aeruginosa strain. Antimicrob. Agents Chemother. 41:785-790.[Abstract]
    5. 5
  5. Danel, F., L. M. Hall, D. Gur, and D. M. Livermore. 1998. OXA-16, a further extended-spectrum variant of OXA-10 ß-lactamase, from two Pseudomonas aeruginosa isolates. Antimicrob. Agents Chemother. 42:3117-3122.[Abstract/Free Full Text]
    6. 6
  6. Danel, F., L. M. Hall, B. Duke, D. Gur, and D. M. Livermore. 1999. OXA-17, a further extended-spectrum variant of OXA-10 ß-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1362-1366.[Abstract/Free Full Text]
    7. 7
  7. Hall, L. M. C., D. M. Livermore, D. Gur, M. Akova, and H. E. Akalin. 1993. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) ß-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37:1637-1644.[Abstract/Free Full Text]
    8. 8
  8. Kiewitz, C., and B. Tümmler. 2000. Sequence diversity of Pseudomonas aeruginosa: impact on population structure and genome evolution. J. Bacteriol. 182:3125-3135.[Abstract/Free Full Text]
    9. 9
  9. Labia, R., J. Andrillon, and F. Le Goffic. 1973. Computerized microacidimetric determination of ß-lactamase Michaelis-Menten constants. FEBS Lett. 33:42-44.[CrossRef][Medline]
    10. 10
  10. Lauretti, L., M. L. Riccio, A. Mazzariol, G. Cornaglia, G. Amicosante, R. Fontana, and G. M. Rossolini. 1999. Cloning and characterization of blaVIM, a new integron-borne metallo-ß-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 43:1584-1590.[Abstract/Free Full Text]
    11. 11
  11. Livermore, D. M., and N. Woodford. 2000. Carbapenemases: a problem in waiting? Curr. Opin. Microbiol. 3:489-495.D. M.[CrossRef][Medline]
    12. 12
  12. Livermore, D. M. 2001. Of Pseudomonas, porins pumps and carbapenems. J. Antimicrob. Chemother. 47:247-250.[Free Full Text]
    13. 13
  13. Luzzaro, F., E. Mantengoli, M. Perilli, G. Lombardi, V. Orlandi, A. Orsatti, G. Amicosante, G. M. Rossolini, and A. Toniolo. 2001. Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum ß-lactamase. J. Clin. Microbiol. 39:1865-1870.[Abstract/Free Full Text]
    14. 14
  14. Mahenthiralingam, E., M. E. Campbell, J. Foster, J. S. Lam, and D. P. Speert. 1996. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J. Clin. Microbiol. 34:1129-1135.[Abstract]
    15. 15
  15. Marchandin, H., H. Jean-Pierre, C. De Champs, D. Sirot, H. Darbas, P. F. Perigault, and C. Carriere. 2000. Production of a TEM-24 plasmid-mediated extended-spectrum ß-lactamase by a clinical isolate of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:213-216.[Abstract/Free Full Text]
    16. 16
  16. Mugnier, P., P. Dubrous, I. Casin, G. Arlet, and E. Collatz. 1996. A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:2488-2493.[Abstract]
    17. 17
  17. Mugnier, P., I. Casin, A. T. Bouthors, and E. Collatz. 1998. Novel OXA-10-derived extended-spectrum ß-lactamases selected in vivo or in vitro. Antimicrob. Agents Chemother. 42:3113-3116.[Abstract/Free Full Text]
    18. 18
  18. Nordmann, P., E. Ronco, T. Naas, C. Duport, Y. Michel-Briand, and R. Labia. 1993. Characterization of a novel extended-spectrum ß-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37:962-969.[Abstract/Free Full Text]
    19. 19
  19. Nordmann, P., and M. Guibert. 1998. Extended-spectrum ß-lactamases in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 42:128-131.[Free Full Text]
    20. 20
  20. Philippon, L. N., T. Naas, A. T. Bouthors, V. Barakett, and P. Nordmann. 1997. OXA-18, a class D clavulanic acid-inhibited extended-spectrum ß-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:2188-2195.[Abstract]
    21. 21
  21. Poirel, L., T. Naas, M. Guibert, E. B. Chaibi, R. Labia, and P. Nordmann. 1999. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum beta-lactamase encoded by an Escherichia coli integron gene. Antimicrob. Agents Chemother. 43:573-581.[Abstract/Free Full Text]
    22. 22
  22. Poirel, L., E. Ronco, T. Naas, and P. Nordmann. 1999. Extended-spectrum ß-lactamase TEM-4 in Pseudomonas aeruginosa. Clin. Microbiol. Infect. 5:651-652.[Medline]
    23. 23
  23. Poirel, L., T. Naas, D. Nicolas, L. Collet, S. Bellais, J. D. Cavallo, and P. Nordmann. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-ß-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44:891-897.[Abstract/Free Full Text]
    24. 24
  24. Poirel, L., P. Gerome, C. De Champs, J. Stephanazzi, and P. Nordmann. 2002. Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 ß-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 46:566-569.[Abstract/Free Full Text]
    25. 25
  25. Poirel, L., D. Girlich, T. Naas, and P. Nordmann. 2001. OXA-28, an extended-spectrum variant of OXA-10 ß-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob. Agents Chemother. 45:447-453.[Abstract/Free Full Text]
    26. 26
  26. Poirel, L., G. F. Weldhagen, T. Naas, C. De Champs, M. G. Dove, and P. Nordmann. 2001. Characterization of the class A ß-lactamase GES-2 from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob. Agents Chemother. 45:2965-2968.[Abstract/Free Full Text]
    27. 27
  27. Sirot, J. 1996. Detection of extended-spectrum plasmid-mediated ß-lactamases by disk diffusion. Clin. Microbiol. Infect. 2(Suppl. 1):35-39.
    28. 28
  28. Spangenberg, C., T. C. Montie, and B. Tümmler. 1998. Structural and functional implications of sequence diversity of Pseudomonas aeruginosa genes oriC, ampC and fliC. Electrophoresis 19:545-550.[CrossRef][Medline]
    29. 29
  29. Vahaboglu, H., R. Oztürk, G. Aygün, F. Coskunkan, A. Yaman, A. Kaygusuk, H. Leblebicioglu, I. Balik, K. Aydin, and M. Otkun. 1997. Widespread detection of PER-1-type extended-spectrum ß-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob. Agents Chemother. 41:2265-2269.[Abstract]
    30. 30
  30. Versalovic, J., T. Koeuth, and J. R. Lupski. 1991. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res. 19:6823-6831.[Abstract/Free Full Text]
    31. 31
  31. Vila, J., M. Navia, J. Ruiz, and C. Casals. 1997. Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived ß-lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother. 41:2757-2759.[Abstract]
    32. 32
  32. Walther-Rasmussen, J., A. H. Johnsen, and N. Hoiby. 1999. Terminal truncations in AmpC ß-lactamase from a clinical isolate of Pseudomonas aeruginosa. Eur. J. Biochem. 263:478-485.[Medline]
    33. 33
  33. Watanabe, M., S. Iyobe, M. Inoue, and S. Mitsuhashi. 1991. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 35:147-151.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, September 2002, p. 3031-3034, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3031-3034.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dubois, V., Arpin, C., Dupart, V., Scavelli, A., Coulange, L., Andre, C., Fischer, I., Grobost, F., Brochet, J.-P., Lagrange, I., Dutilh, B., Jullin, J., Noury, P., Larribet, G., Quentin, C. (2008). {beta}-Lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). J Antimicrob Chemother 62: 316-323 [Abstract] [Full Text]  
  • Brasme, L., Nordmann, P., Fidel, F., Lartigue, M. F., Bajolet, O., Poirel, L., Forte, D., Vernet-Garnier, V., Madoux, J., Reveil, J. C., Alba-Sauviat, C., Baudinat, I., Bineau, P., Bouquigny-Saison, C., Eloy, C., Lafaurie, C., Simeon, D., Verquin, J. P., Noel, F., Strady, C., De Champs, C. (2007). Incidence of class A extended-spectrum {beta}-lactamases in Champagne-Ardenne (France): a 1 year prospective study. J Antimicrob Chemother 60: 956-964 [Abstract] [Full Text]  
  • Henrichfreise, B., Wiegand, I., Pfister, W., Wiedemann, B. (2007). Resistance Mechanisms of Multiresistant Pseudomonas aeruginosa Strains from Germany and Correlation with Hypermutation. Antimicrob. Agents Chemother. 51: 4062-4070 [Abstract] [Full Text]  
  • Henrichfreise, B., Wiegand, I., Luhmer-Becker, I., Wiedemann, B. (2007). Development of Resistance in Wild-Type and Hypermutable Pseudomonas aeruginosa Strains Exposed to Clinical Pharmacokinetic Profiles of Meropenem and Ceftazidime Simulated In Vitro. Antimicrob. Agents Chemother. 51: 3642-3649 [Abstract] [Full Text]  
  • Empel, J., Filczak, K., Mrowka, A., Hryniewicz, W., Livermore, D. M., Gniadkowski, M. (2007). Outbreak of Pseudomonas aeruginosa Infections with PER-1 Extended-Spectrum {beta}-Lactamase in Warsaw, Poland: Further Evidence for an International Clonal Complex. J. Clin. Microbiol. 45: 2829-2834 [Abstract] [Full Text]  
  • Strateva, T., Ouzounova-Raykova, V., Markova, B., Todorova, A., Marteva-Proevska, Y., Mitov, I. (2007). Problematic clinical isolates of Pseudomonas aeruginosa from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. J Med Microbiol 56: 956-963 [Abstract] [Full Text]  
  • Papagiannitsis, C. C., Loli, A., Tzouvelekis, L. S., Tzelepi, E., Arlet, G., Miriagou, V. (2007). SCO-1, a Novel Plasmid-Mediated Class A {beta}-Lactamase with Carbenicillinase Characteristics from Escherichia coli. Antimicrob. Agents Chemother. 51: 2185-2188 [Abstract] [Full Text]  
  • Takeda, S., Nakai, T., Wakai, Y., Ikeda, F., Hatano, K. (2007). In Vitro and In Vivo Activities of a New Cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51: 826-830 [Abstract] [Full Text]  
  • Horianopoulou, M., Legakis, N. J., Kanellopoulou, M., Lambropoulos, S., Tsakris, A., Falagas, M. E. (2006). Frequency and predictors of colonization of the respiratory tract by VIM-2-producing Pseudomonas aeruginosa in patients of a newly established intensive care unit.. J Med Microbiol 55: 1435-1439 [Abstract] [Full Text]  
  • Naas, T., Aubert, D., Lambert, T., Nordmann, P. (2006). Complex Genetic Structures with Repeated Elements, a sul-Type Class 1 Integron, and the blaVEB Extended-Spectrum {beta}-Lactamase Gene.. Antimicrob. Agents Chemother. 50: 1745-1752 [Abstract] [Full Text]  
  • Hocquet, D., Nordmann, P., El Garch, F., Cabanne, L., Plesiat, P. (2006). Involvement of the MexXY-OprM Efflux System in Emergence of Cefepime Resistance in Clinical Strains of Pseudomonas aeruginosa.. Antimicrob. Agents Chemother. 50: 1347-1351 [Abstract] [Full Text]  
  • Brown, S., Amyes, S. (2006). OXA {beta}-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 57: 1-3 [Abstract] [Full Text]  
  • Paterson, D. L., Bonomo, R. A. (2005). Extended-Spectrum {beta}-Lactamases: a Clinical Update. Clin. Microbiol. Rev. 18: 657-686 [Abstract] [Full Text]  
  • Lee, S., Park, Y.-J., Kim, M., Lee, H. K., Han, K., Kang, C. S., Kang, M. W. (2005). Prevalence of Ambler class A and D {beta}-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother 56: 122-127 [Abstract] [Full Text]  
  • Aubert, D., Girlich, D., Naas, T., Nagarajan, S., Nordmann, P. (2004). Functional and Structural Characterization of the Genetic Environment of an Extended-Spectrum {beta}-Lactamase blaVEB Gene from a Pseudomonas aeruginosa Isolate Obtained in India. Antimicrob. Agents Chemother. 48: 3284-3290 [Abstract] [Full Text]  
  • De Champs, C., Chanal, C., Sirot, D., Baraduc, R., Romaszko, J. P., Bonnet, R., Plaidy, A., Boyer, M., Carroy, E., Gbadamassi, M. C., Laluque, S., Oules, O., Poupart, M. C., Villemain, M., Sirot, J. (2004). Frequency and diversity of Class A extended-spectrum {beta}-lactamases in hospitals of the Auvergne, France: a 2 year prospective study. J Antimicrob Chemother 54: 634-639 [Abstract] [Full Text]  
  • Girlich, D., Naas, T., Nordmann, P. (2004). Biochemical Characterization of the Naturally Occurring Oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48: 2043-2048 [Abstract] [Full Text]  
  • Weldhagen, G. F., Poirel, L., Nordmann, P. (2003). Ambler Class A Extended-Spectrum {beta}-Lactamases in Pseudomonas aeruginosa: Novel Developments and Clinical Impact. Antimicrob. Agents Chemother. 47: 2385-2392 [Full Text]  
  • Poirel, L., Menuteau, O., Agoli, N., Cattoen, C., Nordmann, P. (2003). Outbreak of Extended-Spectrum {beta}-Lactamase VEB-1-Producing Isolates of Acinetobacter baumannii in a French Hospital. J. Clin. Microbiol. 41: 3542-3547 [Abstract] [Full Text]  
  • Mammeri, H., Poirel, L., Mangeney, N., Nordmann, P. (2003). Chromosomal Integration of a Cephalosporinase Gene from Acinetobacter baumannii into Oligella urethralis as a Source of Acquired Resistance to {beta}-Lactams. Antimicrob. Agents Chemother. 47: 1536-1542 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Champs, C.
Right arrow Articles by Nordmann, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Champs, C.
Right arrow Articles by Nordmann, P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»